Clarksburg, MD, United States of America

Ravi Kumar Pandrapragada

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Dermbiont, Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Ravi Kumar Pandrapragada

Introduction

Ravi Kumar Pandrapragada is an accomplished inventor based in Clarksburg, MD (US). He has made significant contributions to the field of dermatology through his innovative work. His research focuses on developing compositions and formulations aimed at treating skin diseases, conditions, and disorders.

Latest Patents

Ravi Kumar Pandrapragada holds a patent for "Compositions and formulations for use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders." This patent includes compositions comprising ruboxistaurin free base and its salts, along with methods for treating various skin conditions. He has 1 patent to his name, showcasing his dedication to advancing medical treatments.

Career Highlights

Ravi is currently employed at Dermbiont, Inc., where he continues to innovate in the field of dermatological treatments. His work at the company emphasizes the importance of developing effective solutions for skin-related issues.

Collaborations

Ravi collaborates with notable colleagues, including Karl Beutner and Brendan Philip Brady. These partnerships enhance the research and development efforts at Dermbiont, Inc., contributing to the advancement of skin treatment technologies.

Conclusion

Ravi Kumar Pandrapragada is a prominent figure in the field of dermatology, with a focus on innovative treatments for skin conditions. His contributions through patents and collaborations reflect his commitment to improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…